ENTITY
Antengene

Antengene (6996 HK)

55
Analysis
Health Care • China
Antengene is a global, R&D-driven, commercial-stage biotech company focused on discovering, developing, manufacturing, and commercializing first-in-class/best-in-class therapeutics for hematologic malignancies and solid tumors. Its pipeline includes in-house discovered programs like ATG-022 and ATG-101, and its lead commercial asset is XPOVIO® (selinexor). The company also developed the AnTenGager® T cell engager platform. Antengene is headquartered in Shanghai, China, and was founded in 2017.
more
bullish•Antengene
•06 Nov 2020 07:40

Antengene: Gunning To Move Up in Line

This Insight provides an in-depth review of pre-revenue biotechnology Antegene that plans to list on the HKEX. We discuss the pipeline, market...

Share
bullish•Antengene
•04 Nov 2020 13:59

Antengene (德琪医药) Pre-IPO: Thoughts on Valuation

Antengene is a biotech company with a focus on in-licensed innovative oncology drugs. The company was founded by Dr Jay Mei, an ex-Celgene...

Logo
521 Views
Share
bullish•Antengene
•03 Nov 2020 17:43

Antengene IPO Initiation: Hunting for a Cure

Leveraging the management team’s expertise, Antegene focuses on the haematology and oncology therapeutic areas. Overall, we believe that Antegene’s...

Logo
451 Views
Share
bullish•Ant Group
•01 Nov 2020 11:23

ECM Weekly (1 November 2020) - Ant Group, Sunac Services, New Oriental HK, Bio-Thera

This week, much of the focus is on Ant whereas HK had a disappoint start with the poor debut of KWG Living and Shimao Services. On the other hand,...

Share
bullish•Ant Group
•25 Oct 2020 11:14

ECM Weekly (25 October 2020) - Ant Group, Lufax, JW Thera, Shimao Svcs, GDS Secondary, Nanofilm

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. This week...

Share
x